

Supplementary File 1. Summary table of the risk of bias assessment, based on the Cochrane Systematic Review methodology, for the 12 antipsychotic medications reviewed.

Type of bias	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding (performance bias and detection bias): objective outcomes	Blinding (performance bias and detection bias): subjective outcomes	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Amisulpride							
% low risk studies	10%	10%	100%	0	35%	0	0
% unclear risk studies	90%	90%	0	100%	15%	0	15%
% high risk studies	0	0	0	0	50%	100%	85%
Aripiprazole							
% low risk studies	12.5%	2.5-12.5%	0	7.5%	22.5-80%	12.5-22.5%	0-90%
% unclear risk studies	87.5%	10-90%	95-97%	87.5%	35-87.5%	0-75%	10-90%
% high risk studies	0	5-87.5%	3-5%	5%	7.5-70%	0-87.5%	0-10%

studies							
Asenapine							
% low risk studies	0	0	35%	0	0	20%	0
% unclear risk studies	100%	100%	65%	85%	20%	0	0
% high risk studies	0	0	0	15%	80%	80%	100%
Chlorpromazine							
% low risk studies	12.5-20%	5%	25-65%	10-20%	55-85%	10-65%	20-90%
% unclear risk studies	75-82.5%	90%	27.5%-67.5%	70-90%	0-32.5%	5-50%	5-70%
% high risk studies	2-5%	5%	7.5%	0-10%	12.5-17.5%	25-85%	5-15%
Clozapine							
% low risk studies	62.5%	20%	0	62.5%	62.5%	20%	20%
% unclear risk studies	37.5%	80%	62.5%	20%	20%	42.5%	80%

studies							
% high risk studies	0	0	37.5%	17.5%	17.5%	37.5%	0
Haloperidol							
% low risk studies	0-10%	0	10-65%	5-15%	27.5-30%	5-70%	10-52.5%
% unclear risk studies	80-95%	95-100%	35-55%	70-95%	32.5-35%	0-70%	10-60%
% high risk studies	0-10%	0-5%	0-35%	0-15%	35-40%	25-67.5%	5-37.5%
Olanzapine							
% low risk studies	15%	5%	100%	2.5%	12.5%	10%	0
% unclear risk studies	85%	95%	0	97.5%	15%	2.5%	30%
% high risk studies	0	0	0	0	72.5%	87.5%	70%
Paliperidone							
% low risk	100%	100%	100%	NA	70%	87.5%	0

studies							
% unclear risk	0	0	0		0	0	100%
studies							
% high risk	0	0	0		30%	12.5%	0
studies							
Quetiapine							
% low risk	15-17.5%	7.5-12.5%	0-5%	90%	15-80%	15%	0-62.5%
studies							
% unclear risk	82.5-85%	87.5-92.5%	85-95%	10%	10-70%	20%	0-70%
studies							
% high risk	0	0	0-15%	0	15-55%	65%	30-40%
studies							
Risperidone							
% low risk	12-65%	5-25%	0-100%	100%	10-72.5%	15-80%	0-45%
studies							
% unclear risk	35-88%	75-95%	0-100%	0	25-70%	40-60%	0-80%
studies							
% high risk	0	0	0-65%	0	20-70%	15-80%	12.5-85%
studies							

Ziprasidone							
% low risk studies	0	0	0	100%	0	15%	0
% unclear risk studies	100%	100%	100%	0	15%	0	32.5%
% high risk studies	0	0	0	0	85%	85%	67.5%